000127089 001__ 127089
000127089 005__ 20240228140906.0
000127089 0247_ $$2doi$$a10.1093/annonc/mdv227
000127089 0247_ $$2pmid$$apmid:25962442
000127089 0247_ $$2ISSN$$a0923-7534
000127089 0247_ $$2ISSN$$a1569-8041
000127089 0247_ $$2altmetric$$aaltmetric:3987212
000127089 037__ $$aDKFZ-2017-03115
000127089 041__ $$aeng
000127089 082__ $$a610
000127089 1001_ $$aMeissner, J.$$b0
000127089 245__ $$aLong-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma.
000127089 260__ $$aOxford$$bOxford Univ. Press$$c2015
000127089 3367_ $$2DRIVER$$aarticle
000127089 3367_ $$2DataCite$$aOutput Types/Journal article
000127089 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521705257_16575
000127089 3367_ $$2BibTeX$$aARTICLE
000127089 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127089 3367_ $$00$$2EndNote$$aJournal Article
000127089 520__ $$aChemotherapy-associated ovarian damage comprises not only infertility, but also premature menopause. The latter has been reported as a consequence of alkylating chemotherapy for breast cancer or Hodgkin's lymphoma. In this study, we assessed the long-term impact of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimens on ovarian function in patients with aggressive non-Hodgkin lymphoma (NHL).Long-term survivors after CHOP or CHOP plus etoposide (CHOEP) treatment within the Mabthera International Trial or the NHL-B1 trial of the German NHL Study Group were requested to respond to a questionnaire and to consent to blood sampling for hormone assessment.A total of 46 of 81 contacted patients with a median age of 32.5 years at the time of enrolment into the aforementioned clinical trials responded to the questionnaire. The median follow-up after completion of treatment was 14 years. Last menstrual bleeding occurred significantly earlier in patients compared with the general population (47 versus 51 years, P < 0.0001). In comparison to the distribution of menopausal symptoms in the general population, the percentage of women with moderate or severe menopausal symptoms was increased. In 23 patients who agreed to participate in laboratory analyses, anti-Muller hormone as a marker of ovarian reserve was decreased when compared with correspondent age groups of the general population.Although most female patients regain fertility after CHOP-like chemotherapy, late ovarian impairment occurs frequently. Therefore, awareness of such delayed side-effects at the time of counselling is of importance.
000127089 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000127089 588__ $$aDataset connected to CrossRef, PubMed,
000127089 650_7 $$05J49Q6B70F$$2NLM Chemicals$$aVincristine
000127089 650_7 $$06PLQ3CP4P3$$2NLM Chemicals$$aEtoposide
000127089 650_7 $$080168379AG$$2NLM Chemicals$$aDoxorubicin
000127089 650_7 $$080497-65-0$$2NLM Chemicals$$aAnti-Mullerian Hormone
000127089 650_7 $$08N3DW7272P$$2NLM Chemicals$$aCyclophosphamide
000127089 650_7 $$0VB0R961HZT$$2NLM Chemicals$$aPrednisone
000127089 7001_ $$0P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aTichy, D.$$b1$$udkfz
000127089 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, V.$$b2$$udkfz
000127089 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, T.$$b3$$udkfz
000127089 7001_ $$aDietrich, S.$$b4
000127089 7001_ $$aSchmitt, T.$$b5
000127089 7001_ $$aZiepert, M.$$b6
000127089 7001_ $$aKuhnt, E.$$b7
000127089 7001_ $$aRixecker, T.$$b8
000127089 7001_ $$aZorn, M.$$b9
000127089 7001_ $$aWitzens-Harig, M.$$b10
000127089 7001_ $$aPfreundschuh, M.$$b11
000127089 7001_ $$aHo, A. D.$$b12
000127089 773__ $$0PERI:(DE-600)2003498-2$$a10.1093/annonc/mdv227$$gVol. 26, no. 8, p. 1771 - 1776$$n8$$p1771 - 1776$$tAnnals of oncology$$v26$$x1569-8041$$y2015
000127089 909CO $$ooai:inrepo02.dkfz.de:127089$$pVDB
000127089 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127089 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000127089 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000127089 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000127089 9141_ $$y2015
000127089 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000127089 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000127089 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127089 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127089 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127089 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN ONCOL : 2015
000127089 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000127089 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000127089 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127089 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127089 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127089 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127089 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000127089 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bANN ONCOL : 2015
000127089 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000127089 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x1
000127089 980__ $$ajournal
000127089 980__ $$aVDB
000127089 980__ $$aI:(DE-He78)C060-20160331
000127089 980__ $$aI:(DE-He78)C020-20160331
000127089 980__ $$aUNRESTRICTED